Click here for Prescribing Information


Entresto® (sacubitril/valsartan) resources

Explore our resources designed to provide useful information on Entresto and support with initiation and ongoing treatment.

You can download certain files below for you to share with your patients separately. In order to view these files, you will be required to register. Please do not share links to this website or screenshots with patients, as this website is intended for healthcare professionals only.


Heart to heart icon and text

Resources for GP’s

Watch a selection of useful videos on creating referral letters, reports and alerts in the GP system


 Small screen shot of a video reel

Medical Experts Talking Heads

Watch a selection of videos on heart failure and its management




Indication: Entresto is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.1

HCP, healthcare professional; HFrEF, heart failure with reduced ejection fraction.


  1. Entresto Summary of Product Characteristics, 2021.


Rate this content: 
No votes yet
April 2022 | IE 172569

Ask Speakers


Medical Information Request

Reporting of side effects
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk profile of the medicinal product. All suspected adverse reactions should be reported to HPRA Pharmacovigilance, website Adverse events can also be reported to Novartis preferably at, by emailing [email protected] or by calling (01) 2080 612.